What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

被引：19
作者：
Liu, Joyce F. [1 ]
Matulonis, Ursula A. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 05期
关键词：
Ovarian cancer; PARP inhibitors; Olaparib; Veliparib; Rucaparib; Niraparib; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; RECOMBINATION DNA-REPAIR; NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; FALLOPIAN-TUBE; DOWN-REGULATION; PHASE-II; PRIMARY PERITONEAL;
D O I：
10.1007/s11912-016-0515-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Poly-ADP-ribose polymerase (PARP) inhibitors have been one of the most exciting developments in the treatment of ovarian cancer in recent years. Demonstration of anticancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer.
引用
收藏
页数：9
相关论文
共 47 条
  • [1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
    Abkevich, V.
    Timms, K. M.
    Hennessy, B. T.
    Potter, J.
    Carey, M. S.
    Meyer, L. A.
    Smith-McCune, K.
    Broaddus, R.
    Lu, K. H.
    Chen, J.
    Tran, T. V.
    Williams, D.
    Iliev, D.
    Jammulapati, S.
    FitzGerald, L. M.
    Krivak, T.
    DeLoia, J. A.
    Gutin, A.
    Mills, G. B.
    Lanchbury, J. S.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 107 (10) : 1776 - 1782
  • [2] The PARP superfamily
    Amé, JC
    Spenlehauer, C
    de Murcia, G
    [J]. BIOESSAYS, 2004, 26 (08) : 882 - 893
  • [3] [Anonymous], ANN ONCOLOGY S4, DOI [10.1093/an-nonc/mdu338, DOI 10.1093/ANNONC/MDU338]
  • [4] [Anonymous], 2015, J CLIN ONCOL S
  • [5] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    Audeh, M. William
    Carmichael, James
    Penson, Richard T.
    Friedlander, Michael
    Powell, Bethan
    Bell-McGuinn, Katherine M.
    Scott, Clare
    Weitzel, Jeffrey N.
    Oaknin, Ana
    Loman, Niklas
    Lu, Karen
    Schmutzler, Rita K.
    Matulonis, Ursula
    Wickens, Mark
    Tutt, Andrew
    [J]. LANCET, 2010, 376 (9737) : 245 - 251
  • [6] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615
  • [7] Hypoxia-induced down-regulation of BRCA1 expression by E2Fs
    Bindra, RS
    Gibson, SL
    Meng, A
    Westermark, U
    Jasin, M
    Pierce, AJ
    Bristow, RG
    Classon, MK
    Glazer, PM
    [J]. CANCER RESEARCH, 2005, 65 (24) : 11597 - 11604
  • [8] Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells
    Bindra, RS
    Schaffer, PJ
    Meng, A
    Woo, J
    Måseide, K
    Roth, ME
    Lizardi, P
    Hedley, DW
    Bristow, RG
    Glazer, PM
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (19) : 8504 - 8518
  • [9] Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
    Birkbak, Nicolai J.
    Wang, Zhigang C.
    Kim, Ji-Young
    Eklund, Aron C.
    Li, Qiyuan
    Tian, Ruiyang
    Bowman-Colin, Christian
    Li, Yang
    Greene-Colozzi, April
    Iglehart, J. Dirk
    Tung, Nadine
    Ryan, Paula D.
    Garber, Judy E.
    Silver, Daniel P.
    Szallasi, Zoltan
    Richardson, Andrea L.
    [J]. CANCER DISCOVERY, 2012, 2 (04) : 366 - 375
  • [10] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917
12345